Under the new agreement, Samsung Biologics will offer Pfizer access to supplementary capacity for large-scale manufacturing purposes
The entrance to Pfizer World Headquarters in Manhattan, New York. (Credit: Coolcaesar/ Wikipedia)
Samsung Biologics and Pfizer have unveiled a strategic partnership aimed at facilitating the long-term commercial manufacturing of Pfizer’s diverse range of products.
Building upon their initial manufacturing agreement signed in March 2023 for a specific Pfizer product, the two companies have now expanded their collaboration.
Under the new agreement, Samsung Biologics will offer Pfizer access to supplementary capacity for large-scale manufacturing purposes. The expanded manufacturing capacity will be utilised for the production of a comprehensive portfolio of biosimilars encompassing the fields of oncology, inflammation, and immunology.
Samsung’s facility, known as Plant 4, will serve as the manufacturing hub for these operations.
Samsung Biologics president and CEO John Rim said: “We are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe.
“This new meaningful partnership comes just as our Plant 4 is fully completed early this month as we had previously committed and are on the move for future expansion into our second campus in order to provide our clients with even more flexible and advanced manufacturing technology.”
Pfizer chief global supply officer, executive vice president Mike McDermott said: “Pfizer is excited to continue our strategic partnership with Samsung Biologics Ltd. that aims to enable greater access to medicines for more patients across the world.
“This commitment is a reflection of Pfizer’s trust in the Korean Pharmaceutical industry to address emerging health challenges.”
Pfizer country manager for Korea Dong-Wook Oh said: “Our collaboration with Samsung Biologics will have the potential to significantly improve the lives of patients globally.”